Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection.
Cell Death Differ
; 29(1): 156-166, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1361626
ABSTRACT
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Raloxifene Hydrochloride
/
Estrogen Receptor Modulators
/
Drug Repositioning
/
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Cell Death Differ
Year:
2022
Document Type:
Article
Affiliation country:
S41418-021-00844-6
Similar
MEDLINE
...
LILACS
LIS